Tiago Torres

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7374088/publications.pdf

Version: 2024-02-01

116 papers	2,438 citations	185998 28 h-index	253896 43 g-index
120 all docs	120 docs citations	120 times ranked	3022 citing authors

#	Article	IF	Citations
1	Baricitinib for the treatment of atopic dermatitis. Journal of Dermatological Treatment, 2022, 33, 2404-2413.	1.1	11
2	Patterns of dosage regimen instructions regarding topical medicines: how is the information perceived by patients?. Journal of Dermatological Treatment, 2022, 33, 2325-2330.	1.1	1
3	New Topical Therapies for Psoriasis. American Journal of Clinical Dermatology, 2022, 23, 13-24.	3.3	21
4	Influence of psoriasis lesions' location and severity on psychosocial disability and psychopathology. Observational study and psychometric validation of the SAPASI Portuguese version. Journal of Psychosomatic Research, 2022, 154, 110714.	1.2	1
5	Dupilumab for atopic dermatitis: a real-world Portuguese multicenter retrospective study. Journal of Dermatological Treatment, 2022, , 1-6.	1.1	7
6	Vaccine hesitancy and access to psoriasis care during the <scp>COVID</scp> â€19 pandemic: findings from a global patientâ€reported crossâ€sectional survey. British Journal of Dermatology, 2022, 187, 254-256.	1.4	11
7	Generalized pustular psoriasis: the new era of treatment with IL-36 receptor inhibitors. Journal of Dermatological Treatment, 2022, 33, 2911-2918.	1.1	12
8	Risk of tuberculosis reactivation with interleukin (IL)â€17 and ILâ€23 inhibitors in psoriasis â€“ time for a paradigm change. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 824-834.	1.3	48
9	Factors associated with adverse COVID-19 outcomes in patients with psoriasisâ€”insights from a global registryâ€“based study. Journal of Allergy and Clinical Immunology, 2021, 147, 60-71.	1.5	136
10	Selective IL-13 inhibitors for the treatment of atopic dermatitis. Drugs in Context, 2021, 10, 1-17.	1.0	12
11	Drug Survival of IL-12/23, IL-17 and IL-23 InhibitorsÂfor Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study. American Journal of Clinical Dermatology, 2021, 22, 567-579.	3.3	65
12	Riskâ€mitigating behaviours in people with inflammatory skin and joint disease during the COVIDâ€19 pandemic differ by treatment type: a crossâ€sectional patient survey*. British Journal of Dermatology, 2021, 185, 80-90.	1.4	26
13	An Overview of Bimekizumab for the Treatment of Psoriatic Arthritis: The Evidence so Far. Drug Design, Development and Therapy, 2021, Volume 15, 1045-1053.	2.0	11
14	Targeted Therapy for Pediatric Psoriasis. Paediatric Drugs, 2021, 23, 203-212.	1.3	11
15	Serum Levels of miR-146a in Patients with Psoriasis. Molecular Diagnosis and Therapy, 2021, 25, 475-485.	1.6	7
16	Hydrogels: A Promising Vehicle for the Topical Management of Atopic Dermatitis. Advanced Therapeutics, 2021, 4, 2100028.	1.6	12
17	Pruritic erythematous plaque in the skin folds. Australian Journal of General Practice, 2021, 50, 294-295.	0.3	0
18	Tralokinumab for the Treatment of Atopic Dermatitis. American Journal of Clinical Dermatology, 2021, 22, 625-638.	3.3	15

#	Article	IF	Citations
19	Bimekizumab: the new drug in the biologics armamentarium for psoriasis. Drugs in Context, 2021, 10, 1-4.	1.0	7
20	A case of psoriasis and systemic lupus erythematous successfully treated with ustekinumab. European Journal of Dermatology, 2021, 31, 429-431.	0.3	1
21	Dermatologistsâ€™ attitude towards psoriasis treatment during the COVID-19 pandemic. Drugs in Context, 2021, 10, 1-9.	1.0	3
22	Epigenetic biomarkers as tools for chemical hazard assessment: Gene expression profiling using the model Danio rerio. Science of the Total Environment, 2021, 773, 144830.	3.9	7
23	Describing the burden of the COVIDâ€19 pandemic in people with psoriasis: findings from a global crossâ€sectional study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e636-e640.	1.3	18
24	Does the Vehicle Matter? Real-World Evidence on Adherence to Topical Treatment in Psoriasis. Pharmaceutics, 2021, 13, 1539.	2.0	11
25	Bimekizumab for the Treatment of Psoriasis. Drugs, 2021, 81, 1751-1762.	4.9	18
26	Authorsâ€™ reply to Borg and Thoning: â€œComment on:ÂDrug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Studyâ€• American Journal of Clinical Dermatology, 2021, 22, 903-904.	3.3	1
27	Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib. Dermatology Practical and Conceptual, 2021, 11, e2021145.	0.5	20
28	Portuguese recommendations for the treatment of atopic dermatitis with biologic therapy and JAK inhibitors in adult patients. Drugs in Context, 2021, 10, 1-12.	1.0	1
29	JAK/STAT inhibitors for the treatment of atopic dermatitis. Journal of Dermatological Treatment, 2020, 31, 33-40.	1.1	64
30	Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib. American Journal of Clinical Dermatology, 2020, 21, 783-798.	3.3	73
31	Diagnosis, Screening and Treatment of Patients with Palmoplantar Pustulosis (PPP): A Review of Current Practices and Recommendations . Clinical, Cosmetic and Investigational Dermatology, 2020, Volume 13, 561-578.	0.8	28
32	JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors. Drugs, 2020, 80, 341-352.	4.9	101
33	Managing Cutaneous Immune-Mediated Diseases During theÂCOVID-19 Pandemic. American Journal of Clinical Dermatology, 2020, 21, 307-311.	3.3	60
34	A Systematic Review With Network Meta-Analysis of the Available Biologic Therapies for Psoriatic Disease Domains. Frontiers in Medicine, 2020, 7, 618163.	1.2	14
35	Safety of secukinumab in psoriasis patients with latent tuberculosis infection. European Journal of Dermatology, 2020, 30, 740-741.	0.3	3
36	Oral therapies for psoriasis and psoriatic arthritis: current knowledge and future perspectives. Giornale Italiano Di Dermatologia E Venereologia, 2020, 155, 384-385.	0.8	1

#	Article	IF	Citations
37	The Changing Landscape of Atopic Dermatitis - Focusing on JAK Inhibitors. European Annals of Allergy and Clinical Immunology, 2020, 52, 45.	0.4	5
38	Conjunctivitis in patients with atopic dermatitis treated with dupilumab. Drugs in Context, 2020, 9, 1-8.	1.0	20
39	Psoriasis, biologic therapy, and the pandemic of the 21st century. Drugs in Context, 2020, 9, 1-4.	1.0	7
40	Biosimilars for the treatment of patients with psoriasis: A consensus statement from the Biosimilar Working Group of the International Psoriasis Council. JAAD International, 2020, 1, 224-230.	1.1	3
41	Portuguese recommendations for the treatment of psoriasis with biologic therapy. European Journal of Dermatology, 2020, 30, 645-654.	0.3	4
42	Update on Atopic Dermatitis. Acta Medica Portuguesa, 2019, 32, 606-613.	0.2	126
43	Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis. BioDrugs, 2019, 33, 391-399.	2.2	30
44	Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study. Journal of the American Academy of Dermatology, 2019, 81, 273-275.	0.6	39
45	Biosimilars for Psoriasisâ€"Experience from Europe. Current Dermatology Reports, 2019, 8, 26-34.	1.1	6
46	Mechanical Properties of Topical Anti-Psoriatic Medicines: Implications for Patient Satisfaction with Treatment. AAPS PharmSciTech, 2019, 20, 36.	1.5	17
47	Patient preferences for attributes of topical anti-psoriatic medicines. Journal of Dermatological Treatment, 2019, 30, 659-663.	1.1	15
48	More than skin deep: the systemic nature of atopic dermatitis. European Journal of Dermatology, 2019, 29, 250-258.	0.3	48
49	Dupilumab for atopic dermatitis: evidence to date. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 696-713.	0.8	14
50	Guselkumab for the treatment of psoriasis â€“ evidence to date. Drugs in Context, 2019, 8, 1-11.	1.0	35
51	Guselkumab for the Treatment of Psoriasis. BioDrugs, 2018, 32, 119-128.	2.2	27
52	Dupilumab para el tratamiento de la dermatitis atÃ³pica. Actas Dermo-sifiliogrÃ¡ficas, 2018, 109, 230-240.	0.2	11
53	Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis. American Journal of Clinical Dermatology, 2018, 19, 23-32.	3.3	64
54	Tofacitinib: A New Oral Therapy for Psoriasis. Clinical Drug Investigation, 2018, 38, 101-112.	1.1	23

#	Article	IF	Citations
55	Risk of hepatitis B virus reactivation in patients treated with anti-TNFÎ± agents for immune-mediated inflammatory diseases. Actas Dermo-sifiliogrÃ¡ficas, 2018, 109, 285-287.	0.2	1
56	Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date. Psoriasis: Targets and Therapy, 2018, Volume 8, 83-92.	1.2	9
57	Inhibidores selectivos de la IL-23: los reciÃ©n llegados al tratamiento de la psoriasis. Actas Dermo-sifiliogrÃ¡ficas, 2018, 109, 674-676.	0.2	1
58	Selective Il-23 Inhibitors: The New Kids on the Block in the Treatment of Psoriasis. Actas Dermo-sifiliogrÃ¡ficas, 2018, 109, 674-676.	0.2	3
59	Photo Rounds: Rapid-onset rash in child. Journal of Family Practice, 2018, 67, E1-E2.	0.2	0
60	Clinical Efficacy and Safety of Ixekizumab for Treatment of Psoriasis. Actas Dermo-sifiliogrÃ¡ficas, 2017, 108, 305-314.	0.2	14
61	Methyl-triclosan and triclosan impact embryonic development of Danio rerio and Paracentrotus lividus. Ecotoxicology, 2017, 26, 482-489.	1.1	42
62	Remission of psoriasis after autologous stem cell transplantation - until when?. European Journal of Dermatology, 2017, 27, 74-75.	0.3	5
63	Clinical Efficacy and Safety of Ixekizumab for Treatment of Psoriasis. Actas Dermo-sifiliogrÃ¡ficas, 2017, 108, 305-314.	0.2	2
64	Pediatric Psoriasis. American Journal of Clinical Dermatology, 2017, 18, 797-811.	3.3	39
65	Selective Interleukin-23 p19 Inhibition: Another Game Changer in Psoriasis? Focus on Risankizumab. Drugs, 2017, 77, 1493-1503.	4.9	22
66	Awareness and screening attitudes of Portuguese dermatologists on cardiovascular risk factors in psoriatic patients. European Journal of Dermatology, 2017, 27, 443-445.	0.3	1
67	Psoriasis pharmacogenetics: HLA-Cw*0602 as a marker of therapeutic response to ustekinumab. European Journal of Dermatology, 2017, 27, 528-530.	0.3	13
68	Screening the Toxicity of Selected Personal Care Products Using Embryo Bioassays: 4-MBC, Propylparaben and Triclocarban. International Journal of Molecular Sciences, 2016, 17, 1762.	1.8	48
69	Portuguese Position Paper on the Use of Biosimilars in Psoriasis. Acta Medica Portuguesa, 2016, 29, 574-577.	0.2	6
70	A revolutionary therapeutic approach for psoriasis: bispecific biological agents. Expert Opinion on Investigational Drugs, 2016, 25, 751-754.	1.9	46
71	Topical therapy for psoriasis: a promising future. Focus on JAK and phosphodiesterase-4 inhibitors. European Journal of Dermatology, 2016, 26, 3-8.	0.3	19
72	Palmoplantar Psoriasis and Palmoplantar Pustulosis: Current Treatment and Future Prospects. American Journal of Clinical Dermatology, 2016, 17, 349-358.	3.3	71

#	Article	IF	Citations
73	No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents. Expert Opinion on Drug Safety, 2016, 15, 1653-1659.	1.0	39
74	Methodologies for medication adherence evaluation: Focus on psoriasis topical treatment. Journal of Dermatological Science, 2016, 82, 63-68.	1.0	13
75	Importance of educational sessions on cardiometabolic comorbidities. Awareness among psoriasis patients. Actas Dermo-sifiliogrÃ¡ficas, 2016, 107, 539-541.	0.2	0
76	IL-17 Blockade in Psoriasis: Friend or Foe in Cardiovascular Risk?. American Journal of Clinical Dermatology, 2016, 17, 107-112.	3.3	11
77	Psoriasis strikes back! Epicardial adipose tissue: Another contributor to the higher cardiovascular risk in psoriasis. Revista Portuguesa De Cardiologia (English Edition), 2015, 34, 613-616.	0.2	6
78	Small Molecules in the Treatment of Psoriasis. Drug Development Research, 2015, 76, 215-227.	1.4	38
79	The Protective Role of HLA-DRB1<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1" />13 in Autoimmune Diseases. Journal of Immunology Research, 2015, 2015, 1-6.	0.9	57
80	Psoriasis strikes back! Epicardial adipose tissue: Another contributor to the higher cardiovascular risk in psoriasis. Revista Portuguesa De Cardiologia, 2015, 34, 613-616.	0.2	10
81	Epicardial adipose tissue and coronary artery calcification in psoriasis patients. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 270-277.	1.3	38
82	Influence of interleukin-6 gene polymorphisms in epicardial adipose tissue and coronary artery calcification in patients with psoriasis. British Journal of Dermatology, 2015, 172, 534-536.	1.4	4
83	Toxicity screening of Diclofenac, Propranolol, Sertraline and Simvastatin using Danio rerio and Paracentrotus lividus embryo bioassays. Ecotoxicology and Environmental Safety, 2015, 114, 67-74.	2.9	103
84	Nail psoriasis as a predictor of the development of psoriatic arthritis. Actas Dermo-sifiliogrÃ¡ficas, 2015, 106, 452-457.	0.2	59
85	Lack of association between leptin, leptin receptor, adiponectin gene polymorphisms and epicardial adipose tissue, abdominal visceral fat volume and atherosclerotic burden in psoriasis patients. Archives of Physiology and Biochemistry, 2015, 121, 103-108.	1.0	9
86	Nail psoriasis as a predictor of the development of psoriatic arthritis. Actas Dermo-sifiliogrÃ¡ficas, 2015, 106, 452-457.	0.2	1
87	Treatment goals for psoriasis: Should PASI 90 become the standard of care?. Actas Dermo-sifiliogrÃ¡ficas, 2015, 106, 155-157.	0.2	43
88	Biologic therapy for psoriasis - still searching for the best target. Anais Brasileiros De Dermatologia, 2014, 89, 365-367.	0.5	4
89	Erectile dysfunction in psoriasis patients. European Journal of Dermatology, 2014, 24, 482-486.	0.3	22
90	Psoriasis: The visible killer. Revista Portuguesa De Cardiologia, 2014, 33, 95-99.	0.2	12

#	Article	IF	Citations
91	Levels of Physical Activity in Patients with Severe Psoriasis: A Cross-Sectional Questionnaire Study. American Journal of Clinical Dermatology, 2014, 15, 129-135.	3.3	40
92	Psoriasis: The visible killer. Revista Portuguesa De Cardiologia (English Edition), 2014, 33, 95-99.	0.2	6
93	Cardiovascular comorbidities in childhood psoriasis. European Journal of Dermatology, 2014, 24, 229-235.	0.3	30
94	Genetic Markers for Cardiovascular Disease in Psoriasis: The Missing Piece. Molecular Diagnosis and Therapy, 2014, 18, 93-95.	1.6	4
95	Complement C3 as a marker of cardiometabolic risk in psoriasis. Archives of Dermatological Research, 2014, 306, 653-660.	1.1	12
96	Maintenance treatment of psoriasis with cyclosporine A: Comparison between continuous and weekend therapy. Journal of the American Academy of Dermatology, 2013, 68, 341-342.	0.6	23
97	<scp>F</scp>ramingham <scp>R</scp>isk <scp>S</scp>core underestimates cardiovascular disease risk in severe psoriatic patients: Implications in cardiovascular risk factors management and primary prevention of cardiovascular disease. Journal of Dermatology, 2013, 40, 923-926.	0.6	23
98	Treatment of palmoplantar pustulosis with ustekinumab â€“ the importance of interfering with the IL23/Th17 pathway. European Journal of Dermatology, 2013, 23, 916-917.	0.3	4
99	Multiple myeloma in a patient under ustekinumab â€“ are they related?. European Journal of Dermatology, 2013, 23, 567-568.	0.3	2
100	Sacroiliitis in a psoriasis patient after switching from etanercept to ustekinumab. European Journal of Dermatology, 2013, 23, 897-898.	0.3	3
101	Aprepitant: Evidence of its effectiveness in patients with refractory pruritus continues. Journal of the American Academy of Dermatology, 2012, 66, e14-e15.	0.6	54
102	The role of antinuclear autoantibodies in patients with psoriasis treated with antiâ€“tumor necrosis factor-alpha agents: A retrospective long-term study. Journal of the American Academy of Dermatology, 2012, 66, e180-e182.	0.6	14
103	A case of erythrokeratodermia variabilis with connexin 31 gene mutation (Cx31F137L). International Journal of Dermatology, 2012, 51, 494-496.	0.5	2
104	Does treatment of metabolic syndrome components improve psoriasis? Report of three cases.. European Journal of Dermatology, 2012, 22, 270-272.	0.3	4
105	Etanercept-induced asthma in a psoriatic patient resolving with transition to ustekinumab. European Journal of Dermatology, 2012, 22, 696-697.	0.3	6
106	Residentsâ€™ corner November 2011. Residentsâ€™ editorial choice. European Journal of Dermatology, 2011, 21, 1029-1029.	0.3	0
107	Superficial cutaneous leiomyosarcoma of the face: Report of three cases. Journal of Dermatology, 2011, 38, 373-376.	0.6	10
108	Granuloma annulare of the penis â€“ subcutaneous presentation. European Journal of Dermatology, 2011, 21, 448-449.	0.3	3

#	Article	IF	Citations
109	Residentsâ€™ corner September 2011. Residentsâ€™ editorial choice. European Journal of Dermatology, 2011, 21, 826-827.	0.3	0
110	Residentsâ€™ corner September 2011. sQUIZ your knowledge!. European Journal of Dermatology, 2011, 21, 827-828.	0.3	0
111	Tender tumor of the scalp: clinicopathologic challenge. International Journal of Dermatology, 2010, 49, 605-607.	0.5	5
112	Poroceratose superficial disseminada num doente com colangiocarcinoma: manifestaÃ§Ã£o paraneoplÃ¡sica?. Anais Brasileiros De Dermatologia, 2010, 85, 229-231.	0.5	14
113	Tratamento de hidradenite supurativa com infliximab. Anais Brasileiros De Dermatologia, 2010, 85, 576-576.	0.5	7
114	Isolated tongue lesions asÂtheÂsole presentation ofÂsecondary syphilis. European Journal of Dermatology, 2010, 20, 240-241.	0.3	1
115	Widespread comedones asÂtheÂsole clinical manifestation ofÂfollicular mycosis fungoides. European Journal of Dermatology, 2010, 20, 534-535.	0.3	12
116	Paecilomyces lilacinus in transplant patients: an emerging infection. European Journal of Dermatology, 2010, 20, 643-4.	0.3	5